FRAMINGHAM, Mass.--(BUSINESS WIRE)--Variantyx, a leader in genomic precision medicine, today announced the launch of its IriSight™ CNV Analysis - a whole genome-based test for the detection of chromosomal abnormalities that correlate with clinical symptoms manifested in a fetus or a pregnancy, that may result in a genetic disorder or pregnancy loss..

马萨诸塞州弗雷明汉-基因组精准医学的领导者Variantyx今天宣布推出IriSight™ CNV分析-一种基于全基因组的测试，用于检测与胎儿或妊娠中表现出的临床症状相关的染色体异常，可能导致遗传性疾病或妊娠丢失。。

“IriSight™ CNV Analysis provides the first true alternative to CMA,” said Dr. Allan J. Fisher, FACOG, FACMG, Variantyx Medical Director. “Because the entire genome is sequenced, a broader range of chromosomal abnormalities are detected by the test including aneuploidy, unbalanced rearrangements, inversions, deletions/duplications, copy number variants (CNVs), regions of homozygosity and possible uniparental disomy.

“IriSight™ CNV分析为CMA提供了第一个真正的替代方法，”Variantyx医疗总监FACOG的Allan J.Fisher博士说。“由于对整个基因组进行了测序，因此该测试可检测到更广泛的染色体异常，包括非整倍性，不平衡重排，倒位，缺失/重复，拷贝数变异（CNV），纯合区域和可能的单亲二体性。

Reflex options in cases with non-diagnostic outcomes offer the possibility of rapid and seamless, expanded whole genome analysis (WGS) of the already sequenced DNA that includes small sequence changes, mitochondrial variants, and short tandem repeat expansions.”.

在非诊断结果的情况下，反射选项提供了对已经测序的DNA进行快速，无缝，扩展的全基因组分析（WGS）的可能性，其中包括小的序列变化，线粒体变异和短串联重复序列扩展。”。

Chromosomal microarray analysis (CMA) is recommended by both the American College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal-Fetal Medicine (SMFM) for use in prenatal diagnosis. Variantyx’s proprietary whole genome-based platform enables detection of a wider range of chromosomal abnormalities, not just matching but exceeding the capabilities of traditional CMA..

美国妇产科学院（ACOG）和母胎医学会（SMFM）均建议使用染色体微阵列分析（CMA）进行产前诊断。Variantyx专有的基于全基因组的平台可检测更广泛的染色体异常，不仅匹配而且超出了传统CMA的功能。。

About Variantyx

Variantyx

Variantyx is an award-winning, technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to better understand a person’s genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations.

Variantyx是一家获奖的，技术驱动的精准医学公司，为遗传疾病，生殖健康和精准肿瘤学市场提供颠覆性解决方案。Variantyx开发的专有全基因组分析平台使临床医生和患者能够更好地了解一个人的基因组成，从而实现无与伦比的诊断能力和改进的个性化治疗建议。

For more information, please visit www.variantyx.com..

欲了解更多信息，请访问www.variantyx.com。。